RT Journal Article
SR Electronic
T1 Practical guidance on the use of faecal calprotectin
JF Frontline Gastroenterology
JO Frontline Gastroenterol
FD BMJ Publishing Group Ltd
SP 87
OP 91
DO 10.1136/flgastro-2016-100762
VO 9
IS 2
A1 Matthew J Brookes
A1 Simon Whitehead
A1 Daniel R Gaya
A1 Antony Barney Hawthorne
YR 2018
UL http://fg.bmj.com/content/9/2/87.abstract
AB Differentiation between inflammatory bowel disease (IBD) and functional gut disorders, and the determination of mucosal disease activity in established cases of IBD remain the cornerstones of disease diagnosis and management. Non-invasive, accurate biomarkers of gut inflammation are needed due to the variability of symptoms, the inaccuracies of currently available blood markers and the cost and invasive nature of endoscopy. Numerous biomarkers have been used and/or considered with some in current use. This article reviews the current evidence base around the indications for using biomarkers and their limitations, with a particular focus on faecal calprotectin.